At ASCO 2017 clinicians present new evidence about Watson cognitive technology and cancer care

IBM Watson Health (NYSE: IBM) and its collaborators today unveiled data that will be presented at ASCO 2017, demonstrating the clinical utility of Watson for Oncology trained by Memorial Sloan Kettering as well as Watson for Clinical Trial Matching (CTM). IBM also announced the latest updates on adoption of Watson oncology offerings,
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Business Business and Industry Source Type: news